retatrutide phase 2 trial weight loss 🚨 is out: 24.2% mean and a quarter lost >30%! Women lost more weight than men. #ADA2023 was like drinking from a fire hose for emerging anti-obesity Experimental drug Retatrutide shows promising

A 2021 review of 13 studies reached a similar conclusion, finding that GLP-1 receptor agonist treatment caused between 11.2 to 13.6 pounds of weight loss over periods ranging from 12 to 68 weeks

One is Virta Health, which advertises its nutrition-focused weight management program as a proven approach for deprescribing GLP-1s when clinically appropriate. A Virta-funded study assessed 154 people with Type 2 diabetes who stopped using GLP-1 medications but continued following Virtas program, concluding that their weight did not significantly increase after a year

This gradual increase helps to reduce possible nausea or digestive discomfort while still allowing semaglutide to suppress your appetite

They are both usually administered as weekly injections

This is why semaglutide was originally developed for type 2 diabetes before its appetite suppression effects were recognized

Nutritionists have been a vital piece of that answer for decades